Specifications
Tumor registry query was followed by vital status ascertainment, and medical records review Luminex s -based quantitation from plasma samples was conducted for the following T-helper 1 and T-helper 2 cytokines: Interleukine-2, soluble interleukine-2 receptor α, interleukine-12 subunit p40, interleukine-12 subunit p70, interferon α 2, interferon γ, chemokine ligand 10 (interferon gammainduced protein 10), chemokine ligand 9 (monokine-induced by interferon γ), The dataset included 97 adult females with diabetes mellitus and newly diagnosed breast cancer (cases) and 194 matched controls (breast cancer only). Clinical and treatment history were evaluated in relationship with cancer outcomes and factor-helper 1 and 2 produced cytokine profiles. A biomarker correlation analysis was also performed.
Data source location
United States, Buffalo, NY -42°53 0 50.3592 00 N; 78°52 0 2.658 00 W Data accessibility The data is with this article
Value of the data
This dataset represents the observed relationship between administration of exogenous insulin,
circulating T-helper 1 and 2 produced cytokines at breast cancer diagnosis and cancer outcomes.
The data we present here has the potential to guide future research evaluating the role of insulin in the modulation of type 1 and type 2 immunity.
Our observations can assist further research exploring the relationship between insulin administration and T-helper-driven signaling in breast cancer occurrence.
Data
Reported data represents the observed association between pre-existing use of injectable insulin before breast cancer diagnosis and the T-helper 1 and 2 produced cytokine profiles upon cancer diagnosis in women with both breast cancer and diabetes mellitus ( Table 1) . Data in Table 2 includes the observed correlations between T-helper 1 and 2 cytokines stratified by diabetes mellitus pharmacotherapy and controls.
Experimental design, materials and methods
Evaluation of the association between profiles of T-helper 1 and 2 produced cytokines, injectable insulin use and BC outcomes was carried out under two protocols approved by both Roswell Park Cancer Institute (EDR154409 and NHR009010) and the State University of New York at Buffalo 
Study population
All incident breast cancer cases diagnosed at Roswell Park Cancer Institute (01/01/2003-12/31/ 2009) were considered for inclusion (n ¼2194). Medical and pharmacotherapy history were used to determine the baseline presence of diabetes.
Inclusion and exclusion criteria
All adult women with pre-existing diabetes at breast cancer diagnosis having available banked treatment-naïve plasma specimens (blood collected prior to initiation of any cancer-related therapysurgery, radiation or pharmacotherapy) in the Institute's Data Bank and Bio-Repository were included.
Subjects were excluded if they had prior cancer history or unclear date of diagnosis, incomplete clinical records, type 1 or unclear diabetes status. For a specific breakdown of excluded subjects, please see the original research article by Wintrob et al. [1] .
A total of 97 female subjects with breast cancer and baseline diabetes mellitus were eligible for inclusion in this analysis.
Control-matching approach
Each of the 97 adult female subjects with breast cancer and diabetes mellitus (defined as "cases") was matched with two other female subjects diagnosed with breast cancer, but without baseline diabetes mellitus (defined as "controls"). The following matching criteria were used: age at diagnosis, ; MVP, denotes the p-value of each multivariate adjusted analysis corresponding to the earlier described unadjusted analyses. For more information, please see Section 2.7 below and our previously published analysis work flow [1] . Interleukine-2, IL-2; soluble interleukine-2 receptor α, sIL-2Rα interleukine-12 subunit p40, IL-12p40; interleukine-12 subunit p70, IL-12p70; interferon α 2, IFN-α2; interferon γ, IFN-γ chemokine ligand 10, CXCL-10 (interferon gamma-induced protein 10, IP-10); chemokine ligand 9, CXCL-9 (monokine-induced by interferon γ, MIG); chemokine ligand 8, CXCL-8 (interleukine-8, IL-8); interleukine-5, IL-5; interleukine-10, IL-10; interleukine-13, IL-13. 
Demographic and clinical data collection
Clinical and treatment history was documented as previously described [1] . Briefly, users of any insulin were defined as patients receiving a form of injectable insulinalone or in combinationat the time of breast cancer diagnosis. Vital status was obtained from the Institute's Tumor Registry, a database updated biannually with data obtained from the National Comprehensive Cancer Networks' Oncology Outcomes Database. Outcomes of interest were breast cancer recurrence and/or death. Details regarding patient demographics and clinical characteristics have been previously published [1] .
Plasma specimen storage and retrieval
All the plasma specimens retrieved from long-term storage were individually aliquoted in color coded vials labeled with unique, subject specific barcodes. Overall duration of freezing time was accounted for all matched controls ensuring that the case and matched control specimens had similar overall storage conditions. Only two instances of freeze-thaw were allowed between biobank retrieval and biomarker analyses: aliquoting procedure step and actual assay.
Luminex s assays
A total of 12 biomarkers -interleukine-2, soluble interleukine-2 receptor α, interleukine-12 subunit p40, interleukine-12 subunit p70, interferon α 2, interferon γ, chemokine ligand 10 (interferon gamma-induced protein 10), chemokine ligand 9 (monokine-induced by interferon γ), chemokine ligand 8 (interleukine-8), interleukine-5, interleukine-10, and interleukine-13 -were quantified according to the manufacturer protocol. The Luminex s HCYTOMAG-60K panel (Millipore Corporation, Billerica, MA) was used in this study.
Biomarker-pharmacotherapy association analysis
Biomarker cut-point optimization was performed for each analyzed biomarker. Biomarker levels constituted the continuous independent variable that was subdivided into two groups that optimized the log rank test among all possible cut-point selections yielding a minimum of 10 patients in any resulting group. Quartiles were also constructed. The resultant biomarker categories were then tested for association with type 2 diabetes mellitus therapy and controls by Fisher's exact test. The continuous biomarker levels were also tested for association with diabetes therapy and controls across groups by the Kruskal-Wallis test and pairwise by the Wilcoxon rank sum. Multivariate adjustments Any Insulin (n ¼20) 0.508 0.084 to 0.776 0.018 0.460 À 0.027 to 0.770 0.056
Significant correlations are displayed in bolded text. The differences that are only significant in either adjusted or unadjusted correlations are further denoted by an outline. Interleukine-2, IL-2; soluble interleukine-2 receptor α, sIL-2Rα interleukine-12 subunit p40, IL-12p40; interleukine-12 subunit p70, IL-12p70; interferon α 2, IFN-α2; interferon γ, IFN-γ chemokine ligand 10, CXCL-10 (interferon gamma-induced protein 10, IP-10); chemokine ligand 9, CXCL-9 (monokine-induced by interferon γ, MIG); chemokine ligand 8, CXCL-8 (interleukine-8, IL-8); interleukine-5, IL-5; interleukine-10, IL-10; interleukine-13, IL-13.
were performed accounting for age, tumor stage, body mass index, estrogen receptor status, and cumulative comorbidity. The biomarker analysis was performed using R Version 2.15.3. Please see the original article for an illustration of the analysis workflow [1] . Correlations between biomarkers stratified by type 2 diabetes mellitus pharmacotherapy and controls were assessed by the Pearson method. Correlation models were constructed both with and without adjustment for age, body mass index, and the combined comorbidity index. Correlation analyses were performed using SAS Version 9.4.
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